Valeant Pharmaceuticals International Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (89)

Latest Posts

About This Stock More About This Stock
2,800 Tuesday And The S&P – Are We There Yet?
Article By: Phil Davis
Tuesday, July 10, 2018 10:05 AM EDT
66.6 Thousand. That's the volume the S&P's (SPY) ETF hasn't broken since June.
In this article: VRX, OIL, NDX, SPX, NYA, SPY, DJI
Mizuho Says Synthetic Biologics IBS Treatment May Be 'Interesting' For Valeant
Article By: The Fly
Friday, June 29, 2018 3:13 PM EDT
Mizuho analyst Irina Koffler raised her price target for Valeant Pharmaceuticals.
In this article: VRX, SYN
Valeant Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly
Wednesday, June 6, 2018 8:54 AM EDT
Barclays analyst Douglas Tsao upgraded Valeant Pharmaceuticals to Overweight from Equal Weight and raised his price target for the shares to $29 from $20.
In this article: VRX
Key FDA Events In June Investors Need To Watch Out For
Article By: Zacks Investment Research
Sunday, June 3, 2018 12:49 PM EDT
It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.
In this article: MRK, VRX, ARRY, GWPH, ALKS, AKAO
Deutsche Raises Valeant Price Target On Extended Xifaxan Exclusivity
Article By: The Fly
Monday, April 30, 2018 3:42 PM EDT
The stay in the Xifaxan litigation between Valeant Pharmaceuticals and Teva was recently extended to July 30, 2018, from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note.
In this article: VRX, TEVA

Latest Tweets for $VRX

No tweets yet!